Hypertension Associated Characteristics of Gut Archaea and Their Interaction Network with Bacteria

Wen Yuan[1#], Yihang Chen[1,2#], Jian Meng[3#], Luyun Fan[□#], Hongjie Chi[2#], Jing Li[1,2], Xun Zhang[5], Lin Feng[6], Pixiong Su[2], Jiuchang Zhong[2], Tianhui Li[7], Baicun Li[8*], Xiaoyan Liu[1,9*]

Running Title: Gut Archaea and Hypertension

1. Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

2. Heart Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

3.Chinese Academy of Medical Sciences，Peking Union Medical College，National Key Laboratory of Cardiovascular Diseases，Fuwai Hospital，State Key Laboratory of Cardiovascular Disease，Beijing 100037，China

4. Department of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

5. Heart Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

6. Evidence-Based Medicine Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

7. Institute of Digestive Disease and Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong

8. Center of Respiratory Medicine, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, National Clinical Research Center for Respiratory Diseases, State Key Laboratory of Respiratory Health and Multimorbidity, Beijing 100029, China

9. Department of Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China

Correspondence: Xiaoyan Liu (lxycyyy@mail.ccmu.edu.cn) and Baicun Li (Lbc19890303@126.com) .

Abstract

Background: Hypertension is a major global health challenge and a leading contributor to cardiovascular morbidity and mortality. Increasing evidence indicates that the gut microbiota contributes to the development and progression of hypertension. However, the role of gut archaea, an understudied component of the microbiome, remains poorly defined.

Methods: A total of 246 fecal metagenomic samples from two independent cohorts were analyzed, including 83 healthy controls and 163 individuals with hypertension. Gut archaeal composition, diversity, and interaction networks were assessed, and a diagnostic model was constructed using random forest.

Results: Compared with healthy controls, individuals with hypertension exhibited significantly reduced archaeal richness (Chao1 index, $P = 0.0024$) and distinct community structure (Adonis, $P = 0.011$). Hypertension status was a major host factor associated with

variation in archaeal community composition. Methanobacteriota was the dominant archaeal phylum in both groups. However, key methanogenic archaea, including *Methanobrevibacter_A_smithii,* *Methanosphaera_sp900322125*, and *Methanomassiliicoccus_A_sp905203995*, were significantly depleted in HTN. Hypertension also altered the correlations between gut archaea and clinical indicators, including blood pressure and lipid parameters, and markedly reshaped archaeal–archaeal and archaeal–bacterial interaction networks. A diagnostic model based on three core methanogenic archaeal taxa achieved an AUC of 0.945 in the combined cohort and demonstrated strong performance in the two independent cohorts (AUC = 0.858 and 0.999).

Conclusions: This study provides the first comprehensive characterization of gut archaeal dysbiosis in hypertension. Reduced methanogenic archaea and remodeled cross-domain networks are hallmarks of hypertension. Gut archaeal signatures serve as promising noninvasive biomarkers.

Key Words: hypertension; gut archaeome; gut bacteria; diagnostic biomarker; gut microbiome

Hypertension remains a major global health challenge and is strongly associated with increased risks of cardiovascular disease, stroke, and mortality.[1] The development and progression of hypertension are influenced by a complex interplay of genetic predisposition, lifestyle behaviors, and environmental exposures.[2] In recent years, the gut microbiome has emerged as an important contributor to systemic blood pressure regulation, attracting increasing attention for its role in hypertension pathophysiology.[3–6] Microbial-derived

metabolites are key mediators linking gut microbiota dysbiosis to cardiovascular disease

severity, with trimethylamine N-oxide and imidazole propionate representing

well-characterized examples.[17]

The gut microbiome comprises bacteria, archaea, viruses, and fungi and plays a central

role in host metabolism, immune regulation, and overall health.[7,8] Archaea represent a distinct

and diverse domain of life alongside bacteria and eukaryotes.[9] Although bacterial components

of the microbiome have been extensively investigated, the archaeal fraction offers valuable

insights into the complexity of hypertension. Recent multi-kingdom microbiome studies

indicate that non-bacterial microbial taxa, including archaea and fungi, contribute to disease

pathogenesis. Distinct archaeome and mycobiome signatures have been identified in

conditions such as colorectal cancer and inflammatory bowel disease.[18]

Emerging studies further highlight links between gut archaea and human health.[10] Kim et

al. reported a high abundance of halophilic archaea in the gut archaeome of Korean

individuals.[11] Barnett et al. demonstrated that *Methanobrevibacter smithii* (MSS) is inversely

associated with childhood asthma risk, with higher relative abundance correlating with lower

disease incidence.[12] In colorectal cancer, halophilic archaea are enriched while methanogenic

archaea are depleted, with the halophilic archaeon *Natrinema sp.* J7-2 progressively

increasing from healthy individuals to adenoma and colorectal cancer.[13] Alterations in the gut

archaeal community have also been reported in idiopathic pulmonary arterial hypertension

(IPAH), where multi-kingdom microbial signatures including archaeal taxa provide improved

diagnostic performance compared with single-kingdom markers.[34] Despite these observations,

the relationship between gut archaea and hypertension remains largely undefined.

The present study aimed to characterize gut archaeal profiles in hypertensive and

normotensive individuals and to identify archaeal community alterations associated with

hypertension. Using high-resolution metagenomic sequencing and integrative analytical

approaches in two independent cohorts comprising 246 participants from different geographic

regions,[14] we examined archaeal community composition, diversity, and interactions with gut

bacteria. In addition, we evaluated the potential diagnostic value of archaeal signatures for

hypertension, providing new insights into the role of the gut microbiome in blood pressure

regulation.

Methods

Study Cohorts

Two independent cohorts were included in this study. Cohort 1 was derived from our

previously published investigation conducted in Tangshan and included both hypertensive

patients and healthy individuals.[3] The metagenomic sequencing data for this cohort are

available from the European Nucleotide Archive (ENA) under BioProject accession number

PRJEB13870.[3] Cohort 2 comprised participants from Dalian, China, including hypertensive

patients and healthy controls; fecal metagenomic sequencing data for this cohort were

obtained from the ENA under accession number PRJEB21612.[5] As all participants were

drawn from these previously published studies, which had obtained ethical approval from

their respective institutional review boards, the present study involved no additional human

subject recruitment or data collection and was therefore exempt from further ethical review.

In both cohorts, healthy controls were defined as individuals not receiving

antihypertensive treatment with systolic blood pressure (SBP) ≤120 mmHg and diastolic

blood pressure (DBP) ≤80 mmHg. Hypertension (HTN) was defined according to the 2025

American College of Cardiology/American Heart Association (ACC/AHA) guidelines as

≥130 mmHg or DBP ≥80 mmHg in the absence of antihypertensive medication.[35]

Data Preprocessing and Microbial Taxonomic Analysis

Data preprocessing and microbial taxonomic profiling were performed as previously

described.[33] Metagenomic datasets obtained from the ENA public database and in-house

sequencing were quality filtered using KneadData v0.10.0 with default parameters to remove

host-derived sequences and low-quality reads. To improve archaeal taxonomic resolution, a

custom Kraken–GTDB reference database was constructed using Genome Taxonomy

Database (GTDB) version 214 genomes.[14] To minimize sequence misclassification, fungal

and viral genomes from the NCBI RefSeq database were also incorporated.[15] The final

database included 394,932 genomes representing 80,789 bacterial species, 7,777 genomes

representing 4,416 archaeal species, 9,346 viral reference genomes, and 1,094 fungal

reference genomes. Shotgun metagenomic reads were classified using Kraken2 v2.1.2beta

with a confidence threshold of 0.05.[16] Species abundances at each taxonomic level were

subsequently re-estimated using Bracken v2.5.3 with default parameters (k=35, l=60).

Archaeal and bacterial abundance profiles were then extracted separately for downstream

analyses.

Diversity and Structural Analysis of Gut Archaeal Communities

Community diversity was assessed using α-diversity and β-diversity metrics based on

archaeal species abundance. Community richness and evenness were evaluated using the

Chao1 and Shannon indices, respectively, and intergroup differences were tested using the

Wilcoxon rank-sum test. β-diversity was examined using principal coordinates analysis (PCoA) based on Bray–Curtis distance to visualize differences in archaeal community structure between HC and HTN individuals. Statistical significance of community differences was evaluated using Adonis (Permutational Multivariate Analysis of Variance, PERMANOVA) with 999 permutations. PERMANOVA was also applied to assess the marginal explanatory power of clinical variables, including study cohort, hypertension status, age, sex, body mass index (BMI), and glycolipid metabolic indicators, on archaeal community variation.

Archaeal and Bacterial Enterotype Analysis

Unsupervised clustering using Partitioning Around Medoids (PAM) was applied to species-level relative abundance profiles to classify archaeal and bacterial enterotypes. The optimal number of clusters was determined using the Calinski–Harabasz (CH) index. Participants were ultimately categorized into two archaeal enterotypes (Ar-C1 and Ar-C2) and two bacterial enterotypes (ET-B and ET-P).

Wilcoxon rank-sum tests were used to identify dominant characteristic species within each enterotype. Chi-square tests were performed to evaluate differences in archaeal enterotype distribution between the HC and HTN groups and to examine associations between archaeal and bacterial enterotypes.

Differential Species Analysis

To identify gut archaeal and bacterial taxa associated with hypertension, relative abundance data were subjected to arcsine square root (AST) transformation and total sum scaling (TSS) normalization. Multivariate Association with Linear Models (MaAsLin2) was

applied to detect taxa with consistent trends across both cohorts, prevalence >10%, and significant associations with hypertension after adjustment for age, sex, BMI, and cohort effects. Wilcoxon rank-sum tests were performed to confirm intergroup abundance differences of key differential species.

Correlation and Interaction Network Analysis

Correlation matrix analyses between gut archaeal taxa and clinical variables, including age, sex, BMI, SBP, DBP, total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and fasting blood glucose (FBG), were performed using OmicStudio (https://www.omicstudio.cn/tool). Differential Gene Correlation Analysis (DGCA) was used to construct archaeal–archaeal and archaeal–bacterial interaction networks separately for HC and HTN groups and to identify associations with significantly strengthened or weakened interactions in HTN. Networks were visualized using Cytoscape.

Co-Association Analysis Between Gut Archaeal and Bacterial Communities

Associations between gut archaeal and bacterial communities were evaluated through two complementary analyses. Pearson correlation analysis was used to assess relationships between α-diversity indices (richness and Shannon index) of archaeal and bacterial communities within HC and HTN groups. Structural concordance between archaeal and bacterial communities was assessed by pairing their PCoA results using Procrustes analysis based on Bray-Curtis distances, with statistical significance evaluated using the Mantel test.

Construction and Validation of a Hypertension Diagnostic Model Based on Gut Archaeal Features

The Boruta algorithm was applied to identify "Confirmed features" among species-level

differential archaeal taxa in the combined cohort. A random forest model was subsequently

used to select key features based on the mean decrease in Gini index (MeanDecreaseGini > 5).

A classification model was constructed using the screened biomarkers. Model performance

was evaluated using 10-fold cross-validation, with receiver operating characteristic (ROC)

curves plotted and the area under the curve (AUC) calculated. Model generalizability was

evaluated independently in Cohort 1 and Cohort 2.

Statistical Analysis

All statistical analyses were performed using R software (version 4.1.0). Normally

distributed continuous variables were reported as mean ± standard deviation and compared

using the t-test. Non-normally distributed variables were expressed as median (interquartile

range) and compared using the Wilcoxon rank-sum test. Categorical variables were

summarized as number (percentage) and analyzed using the chi-square test or Fisher's exact

test. Correlations were assessed using Spearman's rank correlation. All statistical tests were

two-sided, and $P < 0.05$ was considered statistically significant.

Results

Clinical Baseline Characteristics of the Study Cohorts

Two independent cohorts were analyzed: Cohort 1 from a previous study conducted in

Tangshan,[3] and Cohort 2 from Dalian, China, with fecal metagenomic data obtained from the

European Nucleotide Archive (ENA; accession PRJEB21612).[5] Across all samples, the

relative abundance of archaea ranged from 0.06% to 0.25%. To ensure data quality and

analytical reliability, stringent filtering criteria were applied,[33] excluding samples with

missing data, <1 million aligned reads, insufficient archaeal sequencing depth (<800 archaeal

reads), or abnormally elevated archaeal abundance (>1%, indicative of potential

contamination) (Figure 1B).

Following quality control, 135 samples were retained in Cohort 1 (HC: n = 31; HTN: n =

104) and 111 samples in Cohort 2 (HC: n = 52; HTN: n = 59) (Figures 1A–B). The combined

cohort comprised 83 HC and 163 individuals with HTN (Table 1).

Figure 1. Study design and analytical workflow of gut archaeome analysis in hypertension.

A. Study cohorts and reference databases. Cohort 1 included 31 healthy controls (HC) and 104

hypertensive patients (HTN), while Cohort 2 comprised 52 HC and 59 HTN. The integrated reference

database included 80,789 bacterial species, 4,416 archaeal species, 1,094 fungal genomes, and 9,346 viral

genomes. **B.** Sample screening process. Following stringent quality control procedures, 135 samples were

retained from the initial 196 samples in Cohort 1, and 111 samples were retained from the initial 120

samples in Cohort 2. **C.** Analytical workflow. Bioinformatic and statistical analyses included archaeal

community profiling, differential abundance analysis, interspecies co-occurrence network analysis, and

biomarker identification. HC, healthy control; HTN, hypertension.

In Cohort 1, age and BMI did not differ significantly between groups ($P > 0.05$), whereas

the proportion of men was higher in HTN than in HC (94.2% vs. 77.4%, $P < 0.01$). In Cohort

2, no significant differences were observed in age, sex distribution, or BMI ($P > 0.05$). As

expected, SBP and DBP were significantly elevated in HTN compared with HC in both

cohorts ($P < 0.0001$). Among metabolic parameters, triglyceride (TG) levels were higher in

HTN than HC only in Cohort 2 ($P = 0.0155$), whereas fasting blood glucose (FBG),

low-density lipoprotein (LDL), and total cholesterol (TC) did not differ significantly between

groups in either cohort ($P > 0.05$). In the combined cohort, SBP, DBP, and male proportion

remained significantly higher in HTN ($P < 0.01$), with no intergroup differences in age, BMI,

FBG, LDL, or TC ($P > 0.05$) (Table 1).

Cohort	Cohort 1			Cohort 2			All		
	HC	HTN	P value	HC	HTN	P value	HC	HTN	P value
sample size	31	104	N/A	52	59	N/A	83	163	N/A
Male (%)	24 (77.4%)	98 (94.2%)	< 0.01	29 (55.8%)	34 (57.6%)	0.844	53 (63.9%)	132 (81.0%)	< 0.01
Age	54.45± 6.07	53.06± 5.9	0.255	56.06± 8.519	57.17± 9.642	0.524	55.46± 7.696	54.55± 7.713	0.381
BMI	25.620± 3.581	25.76± 3.313	0.839	23.43± 2.708	23.61± 2.893	0.732	24.25± 3.224	24.98± 3.324	0.098
SBP	115.4±7.948	142.0± 17.35	<0.001	111.1± 6.427	163.6± 20.95	<0.001	112.7± 7.290	149.8± 21.37	<0.001
DBP	74.59± 5.674	90.62± 10.14	<0.001	71.19± 6.854	100.2± 11.77	<0.001	72.46± 6.613	94.09± 11.08	<0.001
FGB	5.380± 0.939	5.666± 1.302	0.275	6.208± 2.105	6.476± 2.432	0.539	5.912± 1.815	5.976± 1.854	0.798
LDL	2.680±	2.856±	0.620	2.996±	3.064±	0.622	2.888±	2.932±	0.806

Cohort	Cohort 1			Cohort 2			All		
	HC	HTN	P value	HC	HTN	P value	HC	HTN	P value
	0.787	1.792		0.696	0.756		0.739	1.5	
TG	1.454± 0.876	1.819± 1.847	0.305	1.485± 0.699	1.852± 0.851	0.016	1.474± 0.762	1.831± 1.556	0.054
TC	5.490± 0.930	5.537± 2.388	0.911	4.973± 0.988	5.051± 0.984	0.678	5.158± 0.993	5.360± 2.004	0.394

Table 1. Clinical characteristics of the study population.

Normally distributed variables are presented as mean ± standard deviation, and non-normally distributed

variables are expressed as median (interquartile range). HC, healthy control; HTN, hypertension; BMI,

body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; FBG, fasting blood glucose;

LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol.

Composition of the Gut Archaeal Community in Healthy and Hypertensive Individuals

Gut archaeal community composition was characterized at the phylum, order, and

species levels in the combined cohort (HC = 83; HTN = 163) to define dominant taxa and

intergroup differences (Figure S1).

At the phylum level, Methanobacteriota, Thermoplasmatota, and Halobacteriota

predominated in both groups (Figure S1A), with Methanobacteriota as the most abundant

phylum (HC: 48.73%; HTN: 40.00%).

At the order level, Methanobacteriales was dominant (HC: 48.18%; HTN: 39.61%),

followed by Methanomassiliicoccales (HC: 10.52%; HTN: 11.00%). Other prevalent orders

included Halobacteriales, Nitrososphaerales, and Woesearchaeales, without consistent

intergroup trends (Figure S1B).

At the species level, *Methanobrevibacter_A_sp900766745* was the most abundant taxon

in both groups. In HC, the next most abundant species were *Methanobrevibacter_A_smithii*

and *UBA71_sp006954465*, whereas in HTN they were *UBA71_sp006954465* and

Nitrosotenuis_sp021824845. Notably, *Methanobrevibacter_A_smithii* was markedly reduced

in HTN (4.17%), whereas *Nitrosotenuis_sp021824845* increased from 1.53% in HC to higher

levels in HTN. The predominance of methanogenic and halophilic archaea in both groups

suggests important functional roles for these taxa within the gut microbial ecosystem and their

close association with host physiological status.

Diversity and Structural Characteristics of the Gut Archaeal Community in

Hypertensive Patients

To characterize differences in gut archaeal diversity between hypertensive patients and

healthy individuals, α-diversity and β-diversity analyses were performed in the combined

cohort, and permutational multivariate analysis of variance (PERMANOVA) was applied to

evaluate the contribution of clinical variables to community variation (Figures 2; Figures S2).

α-diversity analysis demonstrated a significant reduction in archaeal richness in the HTN

group compared with HC, as reflected by a lower Chao1 index (Wilcoxon test, $P = 0.0024$;

Figure 2A), whereas community evenness (Shannon index) did not differ significantly

between groups ($P > 0.05$; Figure 2B). These findings indicate that hypertension is associated

with reduced species richness without affecting evenness. β-diversity analysis using PCoA

based on Bray–Curtis distance revealed a clear separation trend in archaeal community

structure between HC and HTN groups (Adonis test, $P = 0.011$; Figure 2C).

PERMANOVA analysis further showed that study cohort exerted the strongest effect on

archaeal community variation ($P = 0.001$), followed by hypertension status ($P = 0.011$),

whereas age, BMI, sex, and glycolipid metabolic indicators did not demonstrate significant

explanatory power ($P > 0.05$) (Figure 2D). Collectively, these results indicate that

hypertension is a key host factor associated with reduced archaeal richness and altered

community structure.

Distribution of Archaeal Enterotypes and Their Association with Bacterial Enterotypes

To investigate archaeal enterotype distribution and its relationship with bacterial

community structure, PAM clustering was performed based on species-level archaeal

abundance profiles, classifying subjects into two archaeal enterotypes: Ar-C1 and Ar-C2

(Figure S2A). Ar-C1 was dominated by *Methanobrevibacter_A_smithii*, whereas Ar-C2 was

characterized by *Methanobrevibacter_A_sp900766745* (Figure 2E). Comparative analysis

showed that Ar-C1 was slightly more prevalent in HC, whereas Ar-C2 was relatively enriched

in HTN; however, these differences did not reach statistical significance (Figure 2F).

Using a similar approach, participants were stratified into two bacterial enterotypes:

ET-B and ET-P (Figure S2B). ET-B was dominated by *Bacteroides_uniformis* and

Phocaeicola_vulgatus (Figures S2C–D), whereas ET-P was characterized by

Prevotella_copri_B, *Prevotella_sp021636625*, and *Prevotella_sp900551275* (Figures S2E–G).

Notably, the archaeal Ar-C1 enterotype was more prevalent within the bacterial ET-P

enterotype (Figure 2G). No significant differences in the distribution of ET-B and ET-P were

observed between HTN and HC groups (Figure 2H). These findings suggest a close

association between archaeal and bacterial enterotype structures.

Figure 2. Diversity and structural characteristics of the gut archaeal community.

A. Chao1 index of the gut archaeal community (Wilcoxon rank-sum test). **B.** Shannon index of the gut archaeal community (Wilcoxon rank-sum test). **C.** Principal coordinates analysis (PCoA) based on Bray–Curtis dissimilarity (Adonis test, R^2 = 0.008, P = 0.011). **D.** Marginal explanatory power of clinical variables on archaeal community variation assessed by PERMANOVA. **E.** Intergroup differences in the relative abundance of two representative archaeal species (Wilcoxon rank-sum test). **F.** Distribution of archaeal enterotypes (Ar-C1, Ar-C2) in the HC and HTN groups (P = 0.0378). **G.** Distribution of bacterial enterotypes (Bac-ET B, Bac-ET P) across archaeal enterotypes (Ar-C1, Ar-C2) (P = 0.5318 for Ar-C1; P = 0.4784 for Ar-C2). **H.** Distribution of bacterial enterotypes (Bac-ET B, Bac-ET P) in the HC and HTN groups. HC, healthy control; HTN, hypertension; PCoA, principal coordinates analysis.

Identification of Hypertension-Associated Differential Gut Archaeal Species

To identify archaeal taxa associated with hypertension, relative abundance data from both individual and combined cohorts were subjected to arcsine square root transformation (AST) and TSS normalization. Multivariate Association with Linear Models (MaAsLin2) was applied after adjusting for age, sex, BMI, and cohort effects. A total of 13 archaeal taxa meeting the criteria of consistent trends across cohorts, prevalence >10%, and significant association with hypertension ($P < 0.05$) were identified (Figure 3A), including 4 species-level and 9 genus-level taxa. Among these, several taxa were significantly depleted in the HTN group, including *Methanosphaera_sp900322125*, *Methanobrevibacter_A_smithii*, *Methanomassiliicoccus_A_sp905203995*, *JABXJT01_sp016840125*, *JABXJT01*, *Methanococcoides*, *Methanoregula*, and *Methanosphaera*. By contrast, taxa enriched in HTN included *Methanobacterium_D*, *PALSA-986*, *UBA184*, *UBA460*, and *18H4-34*.

Wilcoxon rank-sum tests further supported these findings, showing increased trends for *Methanobacterium_D* ($P = 0.056$) and *PALSA-986* ($P = 0.022$), and significantly reduced abundances of *Methanosphaera* ($P = 0.043$) and *Methanobrevibacter_A_smithii* ($P = 0.0034$) in HTN compared with HC (Figures 3B–E). These results confirm that gut archaeal composition is altered in hypertension, with core differential taxa predominantly belonging to methanogenic archaea.

Figure 3. Differential gut archaeal taxa associated with hypertension.

A. Heatmap of archaeal taxa identified by MaAsLin2 after adjustment for confounders (age, sex, BMI,

cohort). **B–E**. Log10-transformed relative abundance comparisons of key taxa between HC and HTN

groups (Wilcoxon rank-sum test): **B.** *g__Methanobacterium_D* (P = 0.056); **C.** *g__Methanosphaera* (P =

0.043); **D.** *g__PALSA-986* (P = 0.022); **E.** *s__Methanobrevibacter_A_smithii* (P = 0.0034). HC, healthy

control; HTN, hypertension.

Correlation Between Gut Archaea and Clinical Indicators, and Archaeal–Archaeal

Interaction Network Analysis

To investigate associations between gut archaea and host clinical parameters, 41 archaeal

species with prevalence >10% and consistent abundance trends across both cohorts were

selected for analysis (Table S1). Spearman correlation analysis was performed between these

taxa and clinical variables, including age, sex, BMI, SBP, DBP, TC, TG, LDL, and FBG

(Figure 4A). Distinct correlation patterns were observed between the HC and HTN groups: In

the HC group, most archaeal taxa exhibited weak correlations with blood pressure indices ($|\rho|$

< 0.2), with only a subset showing moderate associations with age and BMI ($0.2 < |\rho| < 0.4$).

By contrast, in the HTN group, correlations between archaeal taxa and blood pressure

parameters were markedly strengthened, with several taxa demonstrating significant positive

or negative associations with SBP and DBP ($P < 0.05$). Similarly, correlations between

archaeal taxa and lipid parameters (TG, TC, LDL) were more pronounced in the HTN group

than in the HC group. These findings indicate that hypertension is associated with a

substantial reconfiguration of the relationships between gut archaea and host metabolic and

hemodynamic variables.

Archaeal–archaeal interaction networks constructed using DGCA further demonstrated

marked alterations in network structure in the HTN group. Based on changes in association

strength, the network was partitioned into modules of enhanced and weakened interactions

(Figure 4B).

Within the enhanced interaction module, *Methanobrevibacter_A_smithii* and

Methanosphaera_sp900322125 occupied central positions. In the HTN group, correlations

between *Methanobrevibacter_A_smithii* and *Methanosphaera_sp900322125*,

Methanocorpusculum_sp017622255, and *TEKIR-8_sp016839555* were significantly

strengthened. Similarly, *Methanosphaera_sp900322125* exhibited enhanced associations with

Methanobrevibacter_A_smithii, *Methanobrevibacter_sp900314635*,

Methanosphaera_stadtmanae, and *Methanobrevibacter_B_sp900314605*. By contrast, the

weakened interaction module was centered on *Acidiplasma_aeolicum* and

Methanobrevibacter_A_sp002789505. In the HTN group, correlations between

Acidiplasma_aeolicum and *Methanobrevibacter_A_millerae_B*, *TEKIR-8_sp016839555*, and

Nitrosopumilus_sp001541925 were significantly reduced. Likewise, associations between

Methanobrevibacter_A_sp902789505 and *Methanobrevibacter_A_oralis*,

Methanobrevibacter_sp017646885, *UBA71_sp905187815*, and

Methanobrevibacter_A_sp900319535 were significantly weakened (Figure 4B).

Figure 4. Correlation between gut archaea and clinical indicators and archaeal co-occurrence

networks.

A. Heatmap of Spearman correlations between archaeal taxa and clinical indicators, and pairwise archaeal

correlations (left: HC; right: HTN). Red indicates positive correlations, blue indicates negative correlations,

and line thickness reflects correlation strength. **B.** Archaeal co-occurrence network analysis stratified by

abundance trends in HTN relative to HC (upper: increased taxa; lower: decreased taxa; left: HC; right:

HTN). Nodes represent archaeal species (Ar1–Ar34), and edges indicate significant correlations. HC,

healthy control; HTN, hypertension.

Association Between Gut Archaeal and Bacterial Community Diversity and Structure

To further characterize interactions between gut archaeal and bacterial communities

under hypertension, correlations between diversity indices (richness and Shannon index) were

assessed, and structural concordance was evaluated using Procrustes analysis combined with

the Mantel test (Figure S3).

A strong positive correlation between archaeal richness and bacterial richness was

observed in both the HC group (R = 0.83, $P < 2.2e{-}16$) and the HTN group (R = 0.77, $P <$

$2.2e{-}16$) (Figures S3A–B). By contrast, no significant correlation was detected between

archaeal and bacterial Shannon indices in either the HC group (R = 0.067, $P = 0.55$) or the

HTN group (R = -0.11, $P = 0.18$) (Figures S3C–D). These findings indicate a consistent

positive association between archaeal and bacterial richness irrespective of disease status.

Procrustes analysis, supported by Mantel testing, demonstrated significant concordance

between archaeal and bacterial community structures in both the HC and HTN groups

(Figures S3E–F), further supporting coordinated ecological relationships between these microbial domains within the gut ecosystem.

Correlation Between Gut Archaea and Bacteria, and Archaeal–Bacterial Interaction Network Analysis Under Hypertension Status

To evaluate the impact of hypertension on archaeal–bacterial interspecific associations, correlation analyses were performed using 41 archaeal species and 41 bacterial species with consistent abundance trends across both cohorts. Significant differences were observed in archaeal–bacterial correlation patterns ($|\rho| > 0.2$, $P < 0.05$) between the HTN and HC groups. The HC group was characterized predominantly by negative correlations, whereas the HTN group exhibited a predominance of positive correlations (Figure 5A), indicating a marked shift in interdomain association patterns under hypertensive conditions.

DGCA was subsequently applied to identify archaeal–bacterial associations with significantly altered interaction strength in the HTN group. Within the enhanced interaction network, *Nitrosotenuis_sp021824845* and *UBA71_sp006954465* emerged as central nodes, each demonstrating significantly strengthened interactions with multiple bacterial taxa compared with the HC group. Specifically, *Nitrosotenuis_sp021824845* showed enhanced associations with *Dysosmobacter_sp019417795*, *Dysosmobacter_sp900542115*, *Faecalibacterium_sp900539945*, *Gemmiger_sp900539695*, *Lawsonibacter_sp014287875*, *Roseburia_hominis*, *UBA3402_sp003478355*, and *Vescimonas_sp000435555*. Similarly, *UBA71_sp006954465* exhibited strengthened correlations with *CAG-103_sp900543625*, *Faecalibacterium_hattorii*, *Faecalibacterium_sp900539945*, *Lawsonibacter_sp014287875*,

Roseburia_intestinalis,   *Roseburia_sp934317215*,   *UBA3402_sp003478355*,   and

Ventrimonas_sp003478505 (Figure 5B).

By   contrast,   within   the   weakened   interaction   network,

Methanobrevibacter_B_sp900314605 was identified as a central archaeal node. In the HTN

group,   its   interactions   with   *Angelakisella_sp900547385*,   *CAG-103_sp900543625*,

CAG-103_sp900757655,   *CAG-170_sp000432135*,   *CAG-170_sp900545925*,

Dysosmobacter_sp001916835,   *ER4_sp000765235*,   *Faecousia_sp000434635*,   and

Lawsonibacter_sp014287875 were significantly attenuated relative to the HC group (Figure

5B).

Figure 5. Archaeal–bacterial correlations and co-occurrence networks in hypertension.

A. Spearman correlation heatmap of core archaeal and bacterial taxa (left: HC; right: HTN). Red indicates

positive correlations, blue indicates negative correlations, and color intensity reflects correlation strength. **B.**

Archaeon–bacterial co-occurrence networks stratified by abundance trends in HTN relative to HC (upper:

increased taxa; lower: decreased taxa; left: HC; right: HTN). Cyan nodes represent archaeal taxa, purple

nodes represent bacterial taxa, and edge colors denote the direction and magnitude of correlations. HC,

healthy control; HTN, hypertension.

Construction and Validation of a Hypertension Diagnostic Model Based on Gut Archaeal Features

To identify archaeal biomarkers capable of distinguishing hypertensive individuals from

healthy controls, the Boruta algorithm was applied to species-level differential archaeal taxa

in the combined cohort to select "Confirmed features" (Figure 6A). A random forest model

was subsequently used to refine feature selection based on the mean decrease in Gini index

(MeanDecreaseGini > 5). This approach identified three archaeal species as the optimal

feature set: *Methanobrevibacter_A_smithii*, *Methanosphaera_sp900322125*, and

Methanomassiliicoccus_A_sp905203995.

A classification model constructed using these three taxa demonstrated strong

discriminative performance, achieving an area under the receiver operating characteristic

curve (AUC) of 0.945 (95% CI, 0.908–0.945) in the combined cohort (Figure 6B). External

validation confirmed robust generalizability, with an AUC of 0.858 (95% CI, 0.767–0.858) in

Cohort 1 and 0.999 (95% CI, 0.996–0.999) in Cohort 2 (Figures 6C and D). These findings

indicate that the identified archaeal signature provides a stable and effective means of

distinguishing hypertension status across independent populations and supports its potential

utility as a diagnostic biomarker.

Figure 6. Construction and validation of a hypertension diagnostic model based on archaeal taxa.

A. Feature importance ranking of key archaeal taxa in the random forest model. **B.** Receiver operating

characteristic (ROC) curve of the model in the combined cohort (AUC = 0.945; 95% CI, 0.908–0.945). **C.**

External validation in Cohort 1 (AUC = 0.858; 95% CI, 0.767–0.858). **D.** External validation in Cohort 2

(AUC = 0.999; 95% CI, 0.996–0.999). AUC, area under the curve; CI, confidence interval; ROC, receiver

operating characteristic.

Discussion

This study provides a comprehensive characterization of the gut archaeal community in

hypertension, integrating compositional, diversity, and network-level analyses across two

independent cohorts comprising 246 participants. In addition, a diagnostic model based on

archaeal species was established. The findings demonstrate that hypertension is associated

with marked alterations in the gut archaeal community, particularly reductions in

methanogenic archaea, which exhibit close associations with host blood pressure parameters.

These results suggest a potential contributory role of gut archaea in the pathogenesis and

progression of hypertension.

Archaea represent essential yet underexplored constituents of the human gut

microbiota.[19-21] Although many archaeal taxa are adapted to extreme environments,[22] a subset

colonizes moderate ecological niches within the human body, including the gastrointestinal

tract, skin, respiratory tract, and genitourinary system.[23,24] Progress in this field has

historically been constrained by the limited culturability of archaeal species. However,

advances in high-throughput sequencing and metagenomic approaches now enable detailed

interrogation of archaeal community structure and function within complex microbial

ecosystems.[10,13,14,25,26]

Consistent with prior reports, Methanobacteriota was identified as the dominant archaeal

phylum in the gut.[13] Diversity analyses revealed a significant reduction in archaeal richness

(Chao1 index) in the HTN group relative to the HC group, whereas community evenness

(Shannon index) remained unchanged. These findings indicate that hypertension primarily

affects species richness rather than distributional uniformity within the archaeal community, a

pattern also observed in colorectal cancer.[33] PERMANOVA further demonstrated that

hypertension status was a major contributor to archaeal community variation, second only to

cohort-related effects, underscoring its role as a key driver of archaeal community

remodeling.

Differential abundance analyses identified multiple archaeal taxa associated with

hypertension. After adjustment for confounding variables, several methanogenic archaea at

both the genus and species levels were significantly depleted in the HTN group, including

Methanococcoides, *Methanoregula*, *Methanosphaera*, *Methanobrevibacter_A_smithii*,

Methanosphaera_sp900322125, and *Methanomassiliicoccus_A_sp905203995*. By contrast,

several uncultured candidate taxa, including *PALSA-986*, *UBA184*, and *UBA460*, were

enriched in the HTN group. Methanogenic archaea function as primary hydrogen consumers

in the gut and contribute to metabolic homeostasis through syntrophic interactions with

hydrogen-producing bacteria.[31,32] Their depletion may result in hydrogen accumulation, with

downstream effects on short-chain fatty acid (SCFA) production and intestinal barrier

integrity, thereby influencing blood pressure regulation.[28,29] This mechanism is consistent

with the broader paradigm of microbiota-derived metabolites mediating cardiovascular risk,

wherein microbial dysbiosis promotes the generation of pro-hypertensive metabolites.[17]

Enterotype analysis further revealed distinct archaeal community configurations. The

Ar-C1 enterotype, dominated by *Methanobrevibacter_A_smithii,* was more prevalent in the

HC group, whereas the Ar-C2 enterotype, dominated by

Methanobrevibacter_A_sp900766745, was relatively enriched in the HTN group, although the

distribution difference did not reach statistical significance. Notably, archaeal enterotypes

exhibited significant associations with bacterial enterotypes, with Ar-C1 preferentially linked

to the ET-P bacterial enterotype. Complementary Procrustes and Mantel analyses

demonstrated a strong positive correlation in species richness and high concordance in

community structure between archaeal and bacterial communities in both the HC and HTN

groups. These findings highlight the tightly coupled and potentially coevolved relationships

between archaeal and bacterial domains within the gut ecosystem, consistent with

multi-kingdom microbiome studies demonstrating coordinated interdomain interactions in

disease contexts.[18]

Further network-based analyses demonstrated that hypertension profoundly reconfigures

both archaeal–archaeal and archaeal–bacterial interaction patterns. In the HC group, archaeal

taxa exhibited only weak associations with clinical blood pressure parameters, and

archaeal–bacterial interactions were predominantly characterized by negative correlations. By

contrast, in the HTN group, correlations between archaeal taxa and clinical indicators,

including blood pressure and lipid profiles, were markedly strengthened, accompanied by a

shift toward predominantly positive archaeal–bacterial interactions. Notably, interaction

strengths between *Nitrosotenuis_sp021824845* and *UBA71_sp006954465* and canonical

SCFA-producing genera, including *Faecalibacterium* and *Roseburia,* were significantly

increased   in   the   HTN   group.   Conversely,   interactions   between

Methanobrevibacter_B_sp900314605   and   multiple   commensal   bacterial   taxa   were

significantly attenuated.[27,30] These findings suggest that hypertension is associated not only

with compositional alterations in the archaeal community but also with disruption of the

coordinated ecological balance between archaea and bacteria. Such network-level remodeling

may contribute to intestinal microecological instability and promote disease progression.

This study further establishes, for the first time, a hypertension diagnostic model based

on archaeal features. Three key archaeal species identified through Boruta feature selection

and   random   forest   modeling—*Methanobrevibacter_A_smithii*,

Methanosphaera_sp900322125, and *Methanomassiliicoccus_A_sp905203995*—demonstrated

strong discriminative performance in the combined cohort (AUC = 0.945), with consistent

generalizability across two independent cohorts (AUC = 0.858 and 0.999, respectively).

These results highlight the potential of archaeal taxa, as non-bacterial components of the

microbiome, to serve as robust biomarkers for hypertension, particularly in the context of

metabolic-related chronic diseases.

Several limitations warrant consideration. First, this study is observational in design;

although findings were validated across two independent cohorts, causal relationships

between archaeal alterations and hypertension cannot be established. Future studies

incorporating in vivo functional approaches, such as fecal microbiota transplantation in

germ-free models and targeted colonization with specific methanogenic archaea, are required

to elucidate causal mechanisms and assess the direct impact of archaeal taxa on host blood

pressure regulation. Second, all participants were derived from Chinese populations, limiting

the generalizability of these findings. Validation in multi-ethnic, large-scale prospective

cohorts is therefore necessary. Third, the present analysis focused on taxonomic composition

based on metagenomic sequencing and did not address functional gene content, metabolic

pathways, or active metabolite profiles. Integration of multi-omics approaches, including

metatranscriptomics, metabolomics, and metaproteomics, will be essential to further delineate

the mechanistic pathways linking gut archaea to host physiology.

Importantly, the complexity of causal inference must be acknowledged. Although robust

associations between gut archaea and hypertension were identified, the directionality of this

relationship remains unresolved. It is unclear whether archaeal dysbiosis contributes to

hypertension development or arises as a consequence of the hypertensive state. Longitudinal

cohort studies and interventional trials targeting the gut microbiota will be critical to clarify

these relationships and define potential therapeutic implications.

In summary, this study systematically delineates the dysbiotic features of the gut

archaeal community in hypertension, identifies a consistent depletion of methanogenic

archaea, including *Methanobrevibacter_A_smithii,* and demonstrates extensive remodeling of

archaeal–bacterial interaction networks. In addition, a high-performing, non-invasive

diagnostic model based on gut archaeal biomarkers was established. These findings expand

current understanding of the gut microecological contributions to hypertension and provide a

foundation for the development of microbiome-based strategies for early detection, risk

stratification, and targeted intervention. Continued advances in anaerobic archaeal isolation

and functional characterization, together with deeper investigation of host–microbe

interactions, are expected to further position gut archaea as a promising frontier in

cardiovascular metabolic disease research.

Acknowledgments

We thank Phoebe Chi, MD, from Liwen Bianji (Edanz) (www.liwenbianji.cn), for editing a

draft of this manuscript.We thank Edanz for providing English language editing support

during the preparation of this manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (82570072),

and the State Key Laboratory of Respiratory Health and Multimorbidity, State Key

Laboratory Special Fund (2060204).

Disclosures

The authors report no conflicts of interest.

What Is New?

1. This study provides the first comprehensive metagenomic characterization of the human gut

archaeome in hypertension.

2. Hypertension is associated with reduced archaeal richness, depletion of key methanogenic

archaea, and extensive remodeling of archaeal–bacterial networks.

3. A 3-archaeon biomarker panel shows high diagnostic accuracy in two independent cohorts.

What Is Relevant?

1. Gut bacteria contribute to blood pressure regulation, but the role of archaea in hypertension

remains largely unexplored.

2. Methanogenic archaea maintain gut metabolic homeostasis; their depletion may disrupt

microbial balance and promote hypertension.

3. Cross-domain interactions between archaea and bacteria are markedly perturbed in

hypertension.

Clinical Implications

1. Gut archaeal signatures represent promising noninvasive biomarkers for hypertension

screening.

2. Targeted restoration of methanogenic archaea may offer a novel strategy for hypertension

management.

3. These findings expand the microbial basis of hypertension and support translational

applications.

Perspectives

The present study unveils the previously unrecognized landscape of the gut archaeome in

human hypertension, highlighting altered archaeal diversity, reduced methanogenic archaea,

and disrupted archaeal–bacterial cross-domain interactions as key features of hypertension.

These findings expand the microbial framework of blood pressure regulation beyond bacteria

and underscore the potential contribution of archaea to gut metabolic homeostasis and

cardiovascular health. The identified archaeal biomarker panel holds promise as a noninvasive

diagnostic tool for hypertension screening in clinical settings. Further studies are warranted to

verify the causal relationship between archaeal dysbiosis and blood pressure elevation,

explore underlying metabolic and immunological mechanisms, and evaluate whether targeted

modulation of methanogenic archaea can serve as a complementary strategy for hypertension

prevention and management. Collectively, these observations open new avenues for

investigating the archaeome as a novel target in cardiovascular diseases.

605
606
References

1.Dzau VJ, Hodgkinson CP. Precision Hypertension. *Hypertension*. 2024;81(4):702–708. doi:

10.1161/HYPERTENSIONAHA.123.22605

2.Bludorn J, Railey K. Hypertension Guidelines and Interventions. *Primary Care*.

2024;51(1):41–52. doi: 10.1016/j.pop.2023.07.004

3.Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B, Zhang W,

Weldon R, Auguste K, Yang L, Liu X, Chen L, et al. Gut microbiota dysbiosis contributes

to the development of hypertension. *Microbiome*. 2017;5(1):14. doi:

10.1186/s40168-017-0290-7

4.Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang

YL, Sun JY, Liu Y, Zhang WC, Lu HX, et al. Roles of oral microbiota and oral-gut

microbial transmission in hypertension. *J Adv Res*. 2023;43:147–161. doi:

10.1016/j.jare.2022.07.005

5.Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, Han X, Huang Y, Zhao L, Li P, Fang Z, Zhou J,

Guan X, Ding Y, Wang S, Khan M, et al. Alterations of the Gut Microbiome in

Hypertension. *Front Cell Infect Microbiol*. 2017;7:381. doi: 10.3389/fcimb.2017.00381

6.Verhaar B, Prodan A, Nieuwdorp M, Muller M. Gut Microbiota in Hypertension and

Atherosclerosis: A Review. *Nutrients*. 2020;12(10):3000. doi: 10.3390/nu12103000

7.Kuziel GA, Rakoff-Nahoum S. The gut microbiome. *Curr Biol.* 2022;32(6):R260–R265. doi:

10.1016/j.cub.2022.02.037

8.Yousefi Y, Baines KJ, Maleki VS. Microbiome bacterial influencers of host immunity and

response to immunotherapy. *Cell Rep Med.* 2024;10:101487. doi:

10.1016/j.xcrm.2024.101487

9.Spang A, Saw JH, Jorgensen SL, Zaremba-Niedzwiedzka K, Martijn J, Lind AE, van Eijk R,

Schleper C, Guy L, Ettema T. Complex archaea that bridge the gap between prokaryotes

and eukaryotes. *Nature.* 2015;521(7551):173–179. doi: 10.1038/nature14447

10.Fadhlaoui K, Arnal ME, Martineau M, Camponova P, Ollivier B, O'Toole PW, Brugere JF.

Archaea, specific genetic traits, and development of improved bacterial live biotherapeutic

products. *Appl Microbiol Biotechnol.* 2020;104(11):4705–4716. doi:

10.1007/s00253-020-10568-7

11.Kim JY, Whon TW, Lim MY, Kim YB, Kim N, Kwon MS, Kim J, Lee SH, Choi HJ, Nam

IH, Chung WH, Kim JH, Bae JW, Roh SW, Nam YD. The human gut archaeome:

identification of diverse haloarchaea in Korean subjects. *Microbiome.* 2020;8(1):114. doi:

10.1186/s40168-020-00875-8

12.Barnett D, Mommers M, Penders J, Arts I, Thijs C. Intestinal archaea inversely associated

with childhood asthma. *J Allergy Clin Immunol.* 2019;143(6):2305–2307. doi:

10.1016/j.jaci.2019.03.040

13.Coker OO, Wu W, Wong SH, Sung J, Yu J. Altered Gut Archaea Composition and

Interaction With Bacteria Are Associated With Colorectal Cancer. *Gastroenterology.*

2020;159(4):1459–1470. doi: 10.1053/j.gastro.2020.05.024

14.Metch JW, Burrows ND, Murphy CJ, Pruden A, Vikesland PJ. Metagenomic analysis of

microbial communities yields insight into impacts of nanoparticle design. *Nat Nanotechnol*.

2018;13(3):253–259. doi: 10.1038/nnano.2017.247

15.Cortese IJ, Castrillo ML, Onetto AL, Bich GA, Zapata PD, Laczeski ME. De novo genome

assembly of Bacillus altitudinis 19RS3 and Bacillus altitudinis T5S-T4. *PLoS ONE*.

2021;16(3):e0248672. doi: 10.1371/journal.pone.0248672

16.Armstrong G, Martino C, Morris J, Khaleghi B, Kang J, DeReus J, Zhu Q, Roush D,

McDonald D, Gonzalez A, Shaffer JP, Carpenter C, Estaki M, Wandro S, Eilert S, Akel A,

et al. Swapping Metagenomics Preprocessing Pipeline Components Offers Speed and

Sensitivity Increases. *mSystems*. 2022;7(2):e00624-21. doi: 10.1128/mSystems.00624-21

17.Raju SC, Molinaro A, Awoyemi A, Jorgensen SF, Braadland PR, Nendl A, Seljeflot I,

Ueland PM, McCann A, Aukrust P, Vestad B, Mayerhofer C, Broch K, Gullestad L,

Lappegard KT, Halvorsen B, et al. Microbial-derived imidazole propionate links heart

failure-associated microbiome alterations to disease severity. *Genome Med*. 2024;16(1):27.

doi: 10.1186/s13073-024-01461-6

18.Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, Kwong TN, Han J, Liu W, Liu C, She J,

Wong SH, Sung JJ, Yu J. Altered Mycobiota Signatures and Enriched Pathogenic

Aspergillus rambellii Are Associated With Colorectal Cancer. *Gastroenterology*.

2022;163(4):908–921. doi: 10.1053/j.gastro.2022.07.014

19.Maleki S, Razavi SH, Yadav H, Letizia MM. New horizon to the world of gut microbiome.

Crit Rev Food Sci Nutr. 2024:1–19. doi: 10.1080/10408398.2024.2325804

20.Aya JV, Vega LC, Munoz E, Munoz M, Lopez DF, Guzman MP, Martinez DF,

Cruz-Saavedra LB, Castillo AK, Quintero KJ, Gonzalez SR, Cala MP, Ramirez JD.

Divergent Gut Microbiota: Archaeal and Bacterial Signatures Unveiled Unique Patterns in

Colombian Cyclists. *Adv Biol (Weinh)*. 2024. doi: 10.1002/adbi.202400084

21.Hammerhoj A, Gubatan JM, Nielsen OH. Gut Microbiome and Disorders of the

Gastrointestinal   Tract.   *Microorganisms*.   2024;12(3):380.   doi:

10.3390/microorganisms12030380

22.Eme L, Spang A, Lombard J, Stairs CW, Ettema T. Archaea and the origin of eukaryotes.

Nat Rev Microbiol. 2018;16(2):120–134. doi: 10.1038/nrmicro.2017.135

23.Lurie-Weinberger MN, Gophna U. Archaea in and on the Human Body: Health

Implications and Future Directions. *PLoS Pathog*. 2015;11(6):e1004877. doi:

10.1371/journal.ppat.1004877

24.Brochier-Armanet C, Boussau B, Gribaldo S, Forterre P. Mesophilic Crenarchaeota:

proposal for a third archaeal phylum, the Thaumarchaeota. *Nat Rev Microbiol*.

2008;6(3):245–252. doi: 10.1038/nrmicro1839

25.Krawczyk A, Gosiewski T, Zapala B, Kowalska-Duplaga K, Salamon D. Alterations in

intestinal Archaea composition in pediatric patients with Crohn's disease. *Gut Microbes*.

2023;15(2):2276806. doi: 10.1080/19490976.2023.2276806

26.Bai X, Sun Y, Li Y, Li M, Cao Z, Huang Z, Zhang F, Yan P, Wang L, Luo J, Wu J, Fan D,

Chen H, Zhi M, Lan P, Zeng Z, et al. Landscape of the gut archaeome in association with

geography, ethnicity, urbanization, and diet in the Chinese population. *Microbiome*.

2022;10(1):114. doi: 10.1186/s40168-022-01357-2

27.Krawczyk KT, Locht C, Kowalewicz-Kulbat M. Halophilic Archaea Activate Human

Dendritic Cells. *Front Immunol*. 2022;13:833635. doi: 10.3389/fimmu.2022.833635

28.Kowalewicz-Kulbat M, Krawczyk KT, Szulc-Kielbik I, Rykowski S, Denel-Bobrowska M,

Olejniczak AB, Locht C, Klink M. Cytotoxic effects of halophilic archaea metabolites on

ovarian cancer cell lines. *Microb Cell Fact*. 2023;22(1):197. doi:

10.1186/s12934-023-02078-7

29.Poles MZ, Juhasz L, Boros M. Methane and Inflammation. *Intens Care Med Exp*.

2019;7(1):68. doi: 10.1186/s40635-019-0236-9

30.Houshyar Y, Massimino L, Lamparelli LA, Danese S, Ungaro F. Going Beyond Bacteria:

Uncovering the Role of Archaeome and Mycobiome in IBD. *Front Physiol*.

2021;12:783295. doi: 10.3389/fphys.2021.783295

31.Cisek AA, Szymanska E, Aleksandrzak-Piekarczyk T, Cukrowska B. The Role of

Methanogenic Archaea in Inflammatory Bowel Disease. *J Pers Med*. 2024;14(2):218. doi:

10.3390/jpm14020218

32.Borrel G, McCann A, Deane J, Neto MC, Lynch DB, Brugere JF, O'Toole PW. Genomics

and metagenomics of trimethylamine-utilizing Archaea in the human gut. *ISME J*.

2017;11(9):2059–2074. doi: 10.1038/ismej.2017.8

33.Mutengo KH, Masenga SK, Mweemba A, Mutale W, Kirabo A. Gut microbiota dependant

trimethylamine N-oxide and hypertension. *Front Physiol*. 2023;14:1075641. doi:

10.3389/fphys.2023.1075641

34.Luqman A, Hassan A, Ullah M, Naseem S, Ullah M, Zhang L, Din AU, Ullah K, Ahmad W,

Wang G. Role of the intestinal microbiome in cardiovascular disorders. *Front Immunol*.

2024;15:1321395. doi: 10.3389/fimmu.2024.1321395

35.Whelton PK, Carey RM, Aronow WS, et al. 2025 ACC/AHA Guideline for the

Management of Hypertension. *Hypertension*. 2025;85(1):e1–e98. doi:

10.1161/HYPERTENSIONAHA.124.27052